Zealand Pharma announced that its GLP-1 drug, developed in collaboration with Boehringer Ingelheim, achieved an average of 17% weight loss in participants during a late-stage clinical trial.

Investorerne er langt fra tilfredse med de vægttabsdata, som Zealand Pharma har offentliggjort for nyt middel.

Zealand Pharma CEO Says Most-Tolerable Drugs Will Be Next to Win in Obesity Market  WSJ

Shares in Zealand Pharma experienced a significant drop on the stock exchange following the release of disappointing data from its weight-loss drug trials.

Zealand Pharma and FLSmidth have announced transactions related to their respective share buy-back programs. These transactions occurred during week 22 of 2026.

A drug developed by Boehringer Ingelheim and Zealand Pharma demonstrated an average of 16.6% weight loss in patients during a late-stage clinical trial, indicating potential for obesity treatment.

Despite a significant share price drop, Zealand Pharma's CEO remains optimistic, while Novo Nordisk anticipates competition from cheaper generic versions of its weight-loss drugs entering major markets this year.

Zealand Pharma's CEO states that the most tolerable drugs will be the next to succeed in the obesity market.

Zealand Pharma has released its financial results for the full fiscal year.

Zealand Pharma's stock experienced a climb after the company announced a new share buyback program.

Zealand Pharma has announced the appointment of Eric Rojas as its new Vice President and Head of Investor Relations.

Zealand Pharma's shares dropped significantly by 32% following disappointing mid-stage trial results for a weight-loss treatment being developed with Roche.

Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial  WSJ